STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

RegulatorypositivepeptidesPositive

AI Analysis

Summary

An FDA panel recommended that compounding pharmacies be allowed to manufacture two additional peptides, supporting efforts to increase peptide availability. The recommendation aligns with RFK Jr.'s policy goals while Amgen faces separate FDA-related challenges.

Outcome Details

FDA panel recommended allowing compounding pharmacies to make two additional peptides

Importance:5/10

Sentiment:

0.30

FDApeptidescompounding pharmaciesregulatory recommendation

Related Companies

$AMGN

Read the original article

Published by STAT News on July 27, 2026 1:19 PM

Read Original